Drug Trial Radar · NCT00775996
Bioequivalence Study of Clorazepate Dipotassium 15mg Tablets Under Fasting Conditions
Last checked: Nov 20, 2026Latest source record: Oct 20, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Aug 2003
Primary completion
Sep 2003
Study completion Nov 2003
Sponsor
- Lead sponsor
- Ranbaxy Laboratories LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 20, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study was to compare the single-dose relative bioavailability of Ranbaxy and Abbott (TranxeneeT-Tab®) 15 mg clorazepate dipotassium tablets under fasting conditions.
Conditions
- Healthy
Interventions
Clorazepate Dipotassium 15mg TabletsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bioequivalence
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MDS Pharma Services
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.